Format

Send to

Choose Destination
See comment in PubMed Commons below
Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):9253-8. doi: 10.1073/pnas.1323941111. Epub 2014 Jun 9.

Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs.

Author information

  • 1Department of Physiology,Severance Biomedical Research Institute.
  • 2Center for Genome Engineering, Institute for Basic Science, Seoul 151-742, South Korea;Department of Chemistry, Seoul National University, Seoul 151-742, South Korea; and.
  • 3Laboratory of Stem Cell Biology, Division of Biotechnology, College of Life Science and Biotechnology, Korea University, Seoul 136-713, South Korea.
  • 4Department of Physiology,Brain Korea 21 Plus Project for Medical Science, and.
  • 5Department and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul 120-752, South Korea;
  • 6Center for Genome Engineering, Institute for Basic Science, Seoul 151-742, South Korea;Department of Chemistry, Seoul National University, Seoul 151-742, South Korea; and jskim01@snu.ac.kr dwkim2@yuhs.ac.
  • 7Department of Physiology,Severance Biomedical Research Institute,Brain Korea 21 Plus Project for Medical Science, and jskim01@snu.ac.kr dwkim2@yuhs.ac.

Abstract

Hemophilia A, one of the most common genetic bleeding disorders, is caused by various mutations in the blood coagulation factor VIII (F8) gene. Among the genotypes that result in hemophilia A, two different types of chromosomal inversions that involve a portion of the F8 gene are most frequent, accounting for almost half of all severe hemophilia A cases. In this study, we used a transcription activator-like effector nuclease (TALEN) pair to invert a 140-kbp chromosomal segment that spans the portion of the F8 gene in human induced pluripotent stem cells (iPSCs) to create a hemophilia A model cell line. In addition, we reverted the inverted segment back to its normal orientation in the hemophilia model iPSCs using the same TALEN pair. Importantly, we detected the F8 mRNA in cells derived from the reverted iPSCs lines, but not in those derived from the clones with the inverted segment. Thus, we showed that TALENs can be used both for creating disease models associated with chromosomal rearrangements in iPSCs and for correcting genetic defects caused by chromosomal inversions. This strategy provides an iPSC-based novel therapeutic option for the treatment of hemophilia A and other genetic diseases caused by chromosomal inversions.

KEYWORDS:

CRISPR; Cas9; ZFN; genome editing

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk